BioNTech Results Presentation Deck slide image

BioNTech Results Presentation Deck

iNeST I Autogene Cevumeran (BNT122) Phase 1 for Adjuvant Treatment of Pancreatic Cancer 20 Vaccine-induced Neoantigen-specific immune responses of high magnitude against at least one of the neoantigens by ex vivo IFNY ELISPOT in half of the patients. Prolonged Relapse free survival in patients who have high magnitude Immune responses. Number of neoantigens in autogene cevumeran 20 15- 0 Responders (n=8) Non-responders (n=8) iNeST is being developed in collaboration with Genentech. RFS, recurrence-free survival Immunogenic Non-immunogenic No data Balachandran VP, et al. ASCO Annual Meeting 2022; Poster presentation 2516. Investor-initiated single-center study sponsored by Memorial Sloan Kettering Cancer Center IFNy spots x 10 cells 1000 100 10 0 Responders (n=8) 0 * 20 40 60 80 Weeks after surgery *Patient treated in non-protocol-specified sequence 100 100 RFS (%) 50 O No. at risk 8 Responder Non-responder 8 00 00 IL Median RFS: Not reached Median RFS: 13.7 months T 12 18 24 Time (months) (O 6 8 COCO 6 7 5 62 ON 2 RFS from resection (n=16) 1 30 00 BIONTECH
View entire presentation